Tags

Type your tag names separated by a space and hit enter

Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension.
J Hepatol. 1994 Jul; 21(1):88-94.JH

Abstract

An increase in splanchnic blood flow is a physiological response to food intake. In patients with cirrhosis whose hepatic vascular resistance is already high, this increase in flow leads to marked increases in portal pressure. This study investigates whether octreotide prevents the increases in hepatic flow and portal pressure that follow the ingestion of a meal in patients with cirrhosis. Twenty-two patients with cirrhosis and portal hypertension were randomized to receive a mixed liquid meal (520 kcal) plus a single subcutaneous injection of either placebo or octreotide (200 micrograms). In the placebo group the ingestion of a meal was followed by an increase in the hepatic venous pressure gradient (+ 19.4 +/- 4.3%, p < 0.01) and hepatic blood flow (+ 38.2 +/- 14.6%, p < 0.05) at 30 min. In contrast, in the octreotide group eating caused no significant change in the hepatic venous pressure gradient (-2.8 +/- 3.6%, NS), while hepatic flow was decreased (-6.08 +/- 5.4%, p < 0.05). Octreotide blunted the postprandial increase in serum insulin and glucagon levels observed in the placebo group. In conclusion, in patients with cirrhosis and portal hypertension, octreotide prevents the postprandial increase in hepatic blood flow, and consequently also in portal pressure. These findings suggest that this drug could play a role in the long-term management of portal hypertension.

Authors+Show Affiliations

Servicio de Gastroenterología, Clínica Puerta de Hierro, Madrid, Spain.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

7963427

Citation

Albillos, A, et al. "Octreotide Prevents Postprandial Splanchnic Hyperemia in Patients With Portal Hypertension." Journal of Hepatology, vol. 21, no. 1, 1994, pp. 88-94.
Albillos A, Rossi I, Iborra J, et al. Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension. J Hepatol. 1994;21(1):88-94.
Albillos, A., Rossi, I., Iborra, J., Lledó, J. L., Calleja, J. L., Barrios, C., García, P., & Escartín, P. (1994). Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension. Journal of Hepatology, 21(1), 88-94.
Albillos A, et al. Octreotide Prevents Postprandial Splanchnic Hyperemia in Patients With Portal Hypertension. J Hepatol. 1994;21(1):88-94. PubMed PMID: 7963427.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension. AU - Albillos,A, AU - Rossi,I, AU - Iborra,J, AU - Lledó,J L, AU - Calleja,J L, AU - Barrios,C, AU - García,P, AU - Escartín,P, PY - 1994/7/1/pubmed PY - 1994/7/1/medline PY - 1994/7/1/entrez SP - 88 EP - 94 JF - Journal of hepatology JO - J Hepatol VL - 21 IS - 1 N2 - An increase in splanchnic blood flow is a physiological response to food intake. In patients with cirrhosis whose hepatic vascular resistance is already high, this increase in flow leads to marked increases in portal pressure. This study investigates whether octreotide prevents the increases in hepatic flow and portal pressure that follow the ingestion of a meal in patients with cirrhosis. Twenty-two patients with cirrhosis and portal hypertension were randomized to receive a mixed liquid meal (520 kcal) plus a single subcutaneous injection of either placebo or octreotide (200 micrograms). In the placebo group the ingestion of a meal was followed by an increase in the hepatic venous pressure gradient (+ 19.4 +/- 4.3%, p < 0.01) and hepatic blood flow (+ 38.2 +/- 14.6%, p < 0.05) at 30 min. In contrast, in the octreotide group eating caused no significant change in the hepatic venous pressure gradient (-2.8 +/- 3.6%, NS), while hepatic flow was decreased (-6.08 +/- 5.4%, p < 0.05). Octreotide blunted the postprandial increase in serum insulin and glucagon levels observed in the placebo group. In conclusion, in patients with cirrhosis and portal hypertension, octreotide prevents the postprandial increase in hepatic blood flow, and consequently also in portal pressure. These findings suggest that this drug could play a role in the long-term management of portal hypertension. SN - 0168-8278 UR - https://www.unboundmedicine.com/medline/citation/7963427/Octreotide_prevents_postprandial_splanchnic_hyperemia_in_patients_with_portal_hypertension_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0168-8278(94)80142-8 DB - PRIME DP - Unbound Medicine ER -